Literature DB >> 9093771

Elevation of serum ferritin levels as a marker for active systemic lupus erythematosus.

K Nishiya1, K Hashimoto.   

Abstract

OBJECTIVE: To determine the clinical relevance of serum levels of ferritin in patients with systemic lupus erythematosus (SLE) vs. controls, we assessed the correlations between such levels and clinical disease activity, anti-DNA antibody titer, and serum levels of complement.
METHODS: We evaluated 36 patients (3 males and 33 females) with SLE, including 21 patients with active disease. A total of 52 patients (3 males and 49 females) with rheumatoid arthritis (RA) served as controls. In a further study for reproducibility, 15 SLE and 21 RA patients were examined. Serum ferritin levels were measured by a 2-site radioimmunometric assay. Serum levels of C-reactive protein (CRP) were measured semiquantitatively by immunoprecipitation or quantitatively by laser immunonephelometry. Anti-DNA antibody was measured by the Farr assay. CH50 was measured by the hemolytic activity method.
RESULTS: The SLE patients exhibited higher serum levels of ferritin and lower serum levels of CRP than the RA patients. Serum levels of ferritin at the active stage of SLE exceeded those at the inactive stage. The levels of serum ferritin in SLE were positively correlated with the anti-DNA antibody titer and negatively correlated with CH50 values.
CONCLUSION: Serum levels of ferritin appear to provide a useful marker of disease activity in SLE patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9093771

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  9 in total

1.  Hepcidin and Ferritin: Important Mediators in Inflammation Associated Anemia in Systemic Lupus Erythematosus Patients.

Authors:  Neeraja Kunireddy; Rachel Jacob; Siraj Ahmed Khan; B Yadagiri; K S S Sai Baba; I Rajendra Vara Prasad; Iyyapu Krishna Mohan
Journal:  Indian J Clin Biochem       Date:  2017-10-28

2.  The correlation between ferritin level and acute phase parameters in rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Serkan Seyhan; Ömer Nuri Pamuk; Gülsüm Emel Pamuk; Necati Çakır
Journal:  Eur J Rheumatol       Date:  2014-09-01

3.  Macrophage activation syndrome in systemic lupus erythematosus and systemic-onset juvenile idiopathic arthritis: a retrospective study of similarities and dissimilarities.

Authors:  R Naveen; Avinash Jain; Hafis Muhammed; Latika Gupta; Durga P Misra; Able Lawrence; Vikas Agarwal; Ramnath Misra; Amita Aggarwal
Journal:  Rheumatol Int       Date:  2021-01-02       Impact factor: 2.631

4.  Hyperferritinemia is associated with serologic antiphospholipid syndrome in SLE patients.

Authors:  Gisele Zandman-Goddard; Hedi Orbach; Nancy Agmon-Levin; Mona Boaz; Howard Amital; Zoltan Szekanecz; Gabriella Szucs; Josef Rovensky; Emese Kiss; Nadia Corocher; Andrea Doria; Ljudmila Stojanovich; Francesca Ingegnoli; Pier Luigi Meroni; Blaz Rozman; Jesus Gomez-Arbesu; Miri Blank; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

5.  Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus.

Authors:  Chi Chiu Mok; Hui Hua Ding; Marwa Kharboutli; Chandra Mohan
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-07-28       Impact factor: 4.794

6.  Latex agglutination test for ferritin measurement.

Authors:  Nobuo Kotajima; Miki Ishizaka; Setsuko Oshitani; Yukihito Fukumura; Yoshio Ushijima; Masami Murakami
Journal:  J Clin Lab Anal       Date:  2003       Impact factor: 2.352

7.  Inflammation associated anemia and ferritin as disease markers in SLE.

Authors:  Kamala Vanarsa; Yujin Ye; Jie Han; Chun Xie; Chandra Mohan; Tianfu Wu
Journal:  Arthritis Res Ther       Date:  2012-08-07       Impact factor: 5.156

8.  Verification of B-lymphocyte activating factor's involvement in the exacerbation of insulin resistance as well as an autoimmune response in patients with nonalcoholic steatohepatitis and patients with HCV-related chronic liver disease.

Authors:  Takashi Himoto; Koji Fujita; Takako Nomura; Joji Tani; Asahiro Morishita; Hirohito Yoneyama; Reiji Haba; Tsutomu Masaki
Journal:  Diabetol Metab Syndr       Date:  2017-06-13       Impact factor: 3.320

Review 9.  Heme Catabolic Pathway in Inflammation and Immune Disorders.

Authors:  Bing Wu; Yanwei Wu; Wei Tang
Journal:  Front Pharmacol       Date:  2019-07-24       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.